News Releases

Month Year

Email Alerts

Sep 29, 2005

Insmed Issues Statement Regarding IPLEX(TM) Approvable Letter Press Release
Sep 29, 2005

Insmed Provides Update on iPlex Pivotal Trial Data in Severe Primary IGF-1 Deficiency
Sep 25, 2005

Insmed Receives Approvable Letter for iPlex(TM); Conference Call Tomorrow at 8:00am EST
Sep 24, 2005

Insmed Announces Appointment of Dr. Kenneth Attie; Former Genentech Researcher Assumes Role as Medical Director
Sep 19, 2005

SomatoKine(R) Pivotal Data to Be Featured in a Podium Presentation at the ESPE/LWPES 7th Joint Meeting of Pediatric Endocriniology in Lyon, France
Aug 8, 2005

Insmed Incorporated Reports Financial Results for the Second Quarter and First Half of 2005
Aug 2, 2005

Insmed to Release Second Quarter Financial Results; Monday, August 8
Jun 10, 2005

FDA Extends PDUFA Date for SomatoKine to October 03, 2005
May 31, 2005

Insmed Reports Detailed Positive Results from Its Pivotal Clinical Trial of SomatoKine in Patients with Growth Hormone Insensitivity Syndrome
May 25, 2005

Insmed to Present at Needham & Company Biotechnology Conference May 26, 2005
May 24, 2005

Insmed Announces the Continuation of Litigation in the United Kingdom; Judge's Ruling Allows for the Continuation of Legal Action in Suit Filed by Tercica
May 19, 2005

Insmed to Present at UBS Global Pharmaceutical Conference May 23, 2005
May 17, 2005

Insmed Announces Exclusive Option Agreement with UCSF for Series of IGF-1 Receptor Antagonists; Agreement Expands Collaboration on IGF-1 Program in Prostate Cancer
May 10, 2005

Insmed Incorporated Reports Financial Results for First Quarter of 2005
May 5, 2005

Insmed Inc. to Webcast First Quarter Earnings Conference Call Thursday, May 12 at 8:30 a.m. (ET)
Apr 26, 2005

Insmed Initiates Phase II Trial With SomatoKine(R) in Type A Extreme Insulin Resistance
Apr 20, 2005

Insmed Initiates Phase II HIV-Associated Lipodystrophy Trial With Somatokine(R)
Apr 18, 2005

Patent Infringement Suit Against Insmed Dismissed
Apr 13, 2005

FDA Grants Priority Review for Insmed's NDA for SomatoKine for the Treatment of Growth Hormone Insensitivity Syndrome
Mar 16, 2005

Insmed Incorporated Reports Financial Results for Fourth Quarter and Twelve-Months of 2004
Mar 15, 2005

Insmed to Release Fourth Quarter and Year End Financial Results; Wednesday, March 16
Mar 15, 2005

Insmed Announces Completion of $35 Million Financing
Mar 10, 2005

FDA Accepts for Review Insmed's NDA for SomatoKine for the Treatment of Growth Hormone Insensitivity Syndrome
Feb 22, 2005

Insmed Provides Response to United States Patent Lawsuit; Seeks Immediate Dismissal or Summary Judgment for All Claims
Feb 16, 2005

Insmed Provides Response to UK Patent Lawsuit

Show per page

Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your
email alerts.

View the latest Insmed Investor Presentation

Download

Our Global Company

Current Clinical Trials

Our Research Team

Our Global Company

Current Clinical Trials

Our Research Team

Footer